A recent randomized, double-blind trial assessed the efficacy of lactobacillus rhamnosus as an adjunct treatment for plaque psoriasis. The six-month trial, involving 103 patients, evaluated probiotics’ impact, alongside standard care, on skin-lesion improvement and quality of life. Overall, the study found no significant support for the hypothesis that gut microbiome modulation with lactobacillus rhamnosus improves clinical outcomes in psoriasis patients, suggesting the need for further research.
Reference: Suriano ES, Souza MDM, Kobata CM, et al. Efficacy of an adjuvant Lactobacillus rhamnosus formula in improving skin lesions as assessed by PASI in patients with plaque psoriasis from a university-affiliated, tertiary-referral hospital in São Paulo (Brazil): a parallel, double-blind, randomized clinical trial. Arch Dermatol Res. 2023 Aug;315(6):1621-1629. doi: 10.1007/s00403-023-02553-1. Epub 2023 Feb 9. PMID: 36757438.
